Elsevier

Bone

Volume 44, Issue 2, February 2009, Pages 357-363
Bone

Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment

https://doi.org/10.1016/j.bone.2008.10.042Get rights and content

Abstract

Fracture healing in diabetic individuals and in animal models of diabetes is impaired. To investigate mechanisms by which diabetes may affect fracture healing we focused on the transition from cartilage to bone, a midpoint in the fracture healing process. Femoral fractures were induced in mice rendered diabetic by multiple low dose streptozotocin treatment and compared to matching normoglycemic mice. One group of diabetic animals was treated with slow release insulin to maintain normal serum glucose levels. The results indicate that there was relatively little difference in the initial formation of the fracture callus on day 10. However, on day 16 the diabetic group had significantly smaller callus, greater loss of cartilage and enhanced osteoclastogenesis that was normalized by treatment with insulin when assessed by histomorphometric analysis. Chondrocyte apoptosis was significantly higher in diabetic mice and this increase was blocked by insulin. These changes were accompanied by diabetes-increased mRNA levels of RANKL, TNF-α, and ADAMTS-4 and -5 measured by real-time PCR, which was reversed by insulin treatment. On days 16 and 22 bone formation within the callus of diabetic mice was significantly less than the normoglycemic and brought to normal levels by insulin treatment. These results suggest that a significant effect of diabetes on fracture healing is increased chondrocyte apoptosis and osteoclastogenesis that accelerates the loss of cartilage and reduces the anlage for endochondral bone formation during fracture repair. That insulin reverses these effects demonstrates that they are directly related to the diabetic condition.

Introduction

Fracture healing is a complicated multi-phase process that involves the coordinated activity of many cell types [1]. The healing process is initiated by a hematoma that forms in response to the disruption of blood vessels. Progenitors are then recruited to the site of injury where they proliferate and differentiate into chondrocytes and osteoblasts. Chondrocytes produce cartilage forming a soft cartilaginous callus, which calcifies and protects the injured site. As chondrocytes undergo apoptosis osteoclasts begin the removal of mineralized cartilage, setting the stage for endochondral bone formation by osteoblasts. The bony callus then undergoes remodeling until the bone reaches it original form.

Bone is affected by diabetes, which causes osteopenia and impairs fracture healing [2], [3]. Osteopenia is thought to be a contributing factor to the increased fracture risk observed in diabetic patients [4], [5], [6]. Most studies on osteopenia have focused on impaired bone formation, which is supported by a decrease in bone mineral density and reduced markers of bone formation such as serum levels of osteocalcin and alkaline phosphatase [7], [8], [9]. Several mechanisms have been suggested including changes in cell signaling caused by hyperglycemia, inflammation associated with diabetes, changes in circulating growth factors and endocrine hormones, greater oxidative stress and increased cell death [2], [8], [10]. Krakauer et al. have suggested that patients with diabetes have reduced bone formation and bone accumulation during growth, while later in life hyperglycemia leads to increased bone resorption and osteopenia [11]. Recent evidence supports the concept that diabetes can contribute to osteopenia by increasing osteoclast formation [11], [12], [13], [14].

Case reports and clinical investigations have reported that diabetes delays union of healing fractures and increases healing time in diabetic subjects compared to matched controls [5], [15], [16]. Animal models also demonstrate that diabetes leads to the formation of smaller calluses with decreased bone and cartilage formation, decreased proliferation and differentiation of osteoblastic cells and chondrocytes and a two-fold reduction in the mechanical strength during fracture repair in diabetic compared to normoglycemic animals [17], [18], [19], [20], [21]. DNA content is decreased by 40% in healing diabetic fractures compared to controls, an indication that the diabetic calluses have decreased cellularity [22]. This could be due a decrease in the rate of cell proliferation associated with decreased growth factor production [23]. In addition, there is a decrease in the collagen content of the callus of the diabetic animals compared with normoglycemic animals [19], [22]. A decrease in matrix could results from reduced formation of osteoblasts that produce bone [24].

We previously investigated the impact of diabetes on fracture healing in the tibia. The results identified a previously unrecognized catabolic effect of diabetes on fracture repair, the accelerated loss of cartilage in the diabetic group [25]. To investigate further the impact of diabetes on endochondral bone formation experiments were carried out where fractures were induced in the femur and the impact of diabetes was tested by treating mice with slow release insulin. Histologic and molecular analysis indicated that diabetes caused an increased osteoclastogenesis and loss of cartilage and increased mRNA levels of several pro-resorptive factors. Each of these parameters was reversed by treatment with insulin. These studies represent an important extension of our previous results since they demonstrate that the catabolic events are specifically related to the diabetic state since they are rescued by insulin treatment.

Section snippets

Induction of type 1 diabetes

All experiments were approved by the Boston University Medical Center Institutional Animal Care and Use Committee (IACUC). Eight week old, male CD-1 mice purchased from Charles River Laboratories (Wilmington, MA) were rendered diabetic by intraperitoneal injections (i.p.) of streptozotocin (40 mg/kg) (Sigma, St. Louis, MO) in 10 mM citrate buffer daily for 5 days [26]. Control mice were treated identically with vehicle alone, 10 mM citrate buffer. A group of diabetic mice received insulin

Callus and cartilage area

To focus on the transition from cartilage to bone specimens were collected at 10, 16 and 22 days after the fracture. Callus size was assessed at the fracture line and 0.5 mm on the proximal and distal (Fig. 1A). Results from these measurements indicated that the callus size was not significantly different in the diabetic compared to normoglycemic groups on day 10, but just missed statistical significance (P = 0.07). On day 16 the normoglycemic group had 1.8 fold larger callus area per section

Discussion

In patients with diabetes there is an increase risk of fracture [3], [4], [5], [6] and impairment in the fracture healing process [15], [16]. Similar findings have been reported in animal models [19], [20], [22], [29]. Diabetic animals exhibit fracture calluses that are smaller in size than those in normal animals [19], [21], [23]. We found that at an early time point, day 10, the difference between the diabetic and control groups just missed statistical significance. While the cartilage area

Acknowledgments

This work was supported by a grant from National Institute of Arthritis and Musculoskeletal and Skin Diseases, PO1AR049920.

References (43)

  • NicodemusK.K. et al.

    Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women

    Diabetes Care

    (2001)
  • VestergaardP. et al.

    Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

    Diabetologia

    (2005)
  • BotolinS. et al.

    Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice

    Endocrinology

    (2007)
  • KeminkS.A. et al.

    Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology

    J Endocrinol Invest

    (2000)
  • HofbauerL.C. et al.

    Osteoporosis in patients with diabetes mellitus

    J Bone Miner Res

    (2007)
  • McCabeL.R.

    Understanding the pathology and mechanisms of type I diabetic bone loss

    J Cell Biochem

    (2007)
  • KrakauerJ. et al.

    Bone loss and bone turnover in diabetes

    Diabetes

    (1995)
  • GoughA. et al.

    Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy

    Diabet Med

    (1997)
  • JirkovskaA. et al.

    Calcaneal ultrasonometry in patients with Charcot osteoarthropathy and its relationship with densitometry in the lumbar spine and femoral neck and with markers of bone turnover

    Diabet Med

    (2001)
  • LoderR.

    The influence of diabetes mellitus on the healing of closed fractures

    Clin Orthop

    (1988)
  • HerskindA.M. et al.

    Diabetes mellitus and healing of closed fractures

    Diabete Metab

    (1992)
  • Cited by (117)

    • Outcome of fragility hip fractures in elderly patients: Does diabetes mellitus and its severity matter?

      2021, Archives of Gerontology and Geriatrics
      Citation Excerpt :

      DM was found both in animal models and in clinical trials to be associated with an increased risk for poor bone quality and fragility hip fractures (Dhaliwal, Cibula, Ghosh, Weinstock & Moses, 2014; Farr et al., 2014; Gandhi, Beam, O'Connor, Parsons & Lin, 2005; Kayal et al., 2009; Catalina Poiana & Capatina, 2017). Osteoclastogenesis is increased, cartilage is lost, tissue mineralization is decreased, and bone microarchitecture is altered (Dhaliwal et al., 2014; Gandhi et al., 2005; Kayal et al., 2009). In addition, as DM is associated with retinopathy and deterioration in vision, along with neuropathy and cognitive decline in this patient population, it marks an increased risk for falling and sustaining a hip fracture (Bai, Gao, Wang & Dai, 2019; Dytfeld & Michalak, 2017; Jia et al., 2017; C Poiana & Capatina, 2019).

    View all citing articles on Scopus
    View full text